Surrogate End Points in Clinical Research: Hazardous to Your Health

Abstract

Surrogate end points in clinical research pose real danger. A surrogate end point is an outcome measure, commonly a laboratory test, that substitutes for a clinical event of true importance. Resistance to activated protein C, for example, has been used as a surrogate for venous thrombosis in women using oral contraceptives. Other examples of inappropriate surrogate end points in contraception include the postcoital test instead of pregnancy to evaluate new spermicides, breakage and slippage instead of pregnancy to evaluate condoms, and bone mineral density instead of fracture to assess the safety of depo-medroxyprogesterone acetate. None of these markers captures the effect of the treatment on the true outcome. A valid surrogate end point must both correlate with and accurately predict the outcome of interest. Although many surrogate markers correlate with an outcome, few have been shown to capture the effect of a treatment (for example, oral contraceptives) on the outcome (venous thrombosis). As a result, thousands of useless and misleading reports on surrogate end points litter the medical literature. New drugs have been shown to benefit a surrogate marker, but, paradoxically, triple the risk of death. Thousands of patients have died needlessly because of reliance on invalid surrogate markers. Researchers should avoid surrogate end points unless they have been validated; that requires at least one well done trial using both the surrogate and true outcome. The clinical maxim that "a difference to be a difference must make a difference" applies to research as well. Clinical research should focus on outcomes that matter.

Dealing with Missing Outcomes: Lessons from a Randomized Trial of a Prenatal Intervention to Prevent Early Childhood Caries

“…When only a minority of people experience the outcome of interest, any loss to follow-up that exceeds the frequency of that outcome has the potential of creating a two- [29,30]. Not infrequently, intermediate outcomes have led to conclusions that could not be upheld by more substantive assessments later on [30,31].…”

A polycystás ovarium szindróma szövődményeinek prevenciója, kezelése és a kórkép bizonyítékokon alapuló, interdiszciplináris ellátásának fontossága

“…Figyelembe véve az intermedier és a végső eredmény (kemény végpont, outcome) közötti nem egyértelmű kapcsolatra, a PCOS korszerű terápiájá-nál és gondozásánál is törekedni kell a végső eredménye-ket bemutató kutatások megkeresésére és azok eredmé-nyeinek gyakorlati alkalmazására [50,51].…”

Immunostimulation in the era of the metagenome

“…100 However, while surrogate outcomes have some utility in signaling the presence of inflammatory disease, it has become increasingly less clear the extent to which changing a marker associated with disease alters the course of the disease itself; 'few surrogate markers' have been shown to 'capture the effect of a treatment'. 101 More and more researchers and physicians routinely deprecate evidence devoid of outcomes that matter most to patients and their caregivers (i.e., patient-important outcomes). This evolution in approach is borne out of experience.…”

“…According to Grimes and Schulz, 'thousands of useless and misleading reports on surrogate end points litter the medical literature'. 101 While a number of drugs are highly effective at altering measurable metabolites, they barely affect the progression of disease. For example, in low-risk individuals with high cholesterol, statins have a marginal, if not absent, effect in protecting against cardiovascular disease.…”